Site 22, Focus Research Group 201 Signature Place — Lebanon, Tennessee

Site 22, Focus Research Group 201 Signature Place is a clinical research site located in Lebanon, Tennessee, United States 37087.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Site 22, Focus Research Group 201 Signature Place has participated in 1 clinical trials.

Therapeutic areas: Meningococcal Disease.

Sponsors: Novartis Vaccines.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 22, Focus Research Group 201 Signature Place?

Site 22, Focus Research Group 201 Signature Place has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 22, Focus Research Group 201 Signature Place conducted?

Site 22, Focus Research Group 201 Signature Place has 1 clinical trials on record. Their work covers Meningococcal Disease.

Is Site 22, Focus Research Group 201 Signature Place accredited by Crixeo Health?

Site 22, Focus Research Group 201 Signature Place has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 22, Focus Research Group 201 Signature Place?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.